# IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

> **NCT03902184** · PHASE2 · COMPLETED · sponsor: **Innate Pharma** · enrollment: 170 (actual)

## Conditions studied

- Lymphoma, T-Cell
- Lymphoma, T-Cell, Cutaneous
- Mycosis Fungoides/Sezary Syndrome

## Interventions

- **BIOLOGICAL:** IPH4102

## Key facts

- **NCT ID:** NCT03902184
- **Lead sponsor:** Innate Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-22
- **Primary completion:** 2026-01-08
- **Final completion:** 2026-01-08
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03902184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03902184, "IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03902184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*